Hangzhou ApexTide Biomedical Technology Co., Ltd.November 1, 2024

FDA 483 - Hangzhou ApexTide Biomedical Technology Co., Ltd. - November 01, 2024

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Hangzhou ApexTide Biomedical Technology Co., Ltd.

Record Details

An FDA inspection of Hangzhou ApexTide Biomedical Technology Co., Ltd. in Hangzhou, China, revealed significant deficiencies in the manufacturing and quality control of Active Pharmaceutical Ingredients (API). The firm failed to complete process validation, adequately qualify manufacturing areas and equipment, and ensure proper testing of starting materials and water used in production. These issues raise concerns about the quality, purity, and stability of API shipped to the US market.

Company: Hangzhou ApexTide Biomedical Technology Co., Ltd.
Inspection Date: November 1, 2024
Product Type: Drugs
Office: Office of Inspections and Investigations
Person: Nibin Varghese

Open in Dashboard

ID · dfe41cbb-6066-4438-878c-f19ec1361dc5